Neuropathological changes underlying clinical heterogeneity in Alzheimer disease

-
Sponsor: NIH National Institute on Aging

Location(s): United States

Description

Closing critical gaps in the understanding of AD etiopathogenesis by clarifying the neurobiological basis of heterogeneity in AD clinical presentation may result in novel biomarkers and targets for prevention and treatment of this devastating disease. This K24 research and training program will expand the capacity of a productive investigator to train advanced trainees in POR in age-related neuropathology. Furthermore, it will help her to make meaningful progress towards her long-term goal of conquering neurodegenerative diseases by carefully mapping disease-associate lesions in well-characterized human postmortem tissue and correlate these findings with clinical and genetics features.

Dr. Grinberg proposes to use K24 dedicated time to mentor USCF as well as international investigators in patient-oriented dementia research. Her mentees will gain hands-on research experience, expertise in age-related human neuropathology, training in data analysis, manuscript preparation, and grant writing, as well as career, mentoring. Mentee training will leverage the infrastructure and resources of the UCSF/Memory and Aging Center Autopsy program, which is part of ongoing longitudinal cohort studies (P50AG02350 and P01AG019724), and her collaborations with multidisciplinary researchers in the areas of dementia domestically and worldwide. To increase her mentoring skills, she proposes to participate in the UCSF Mentor Development Program. Dr. Grinberg intends to conduct K24-supported Alzheimer's disease research studies that will serve as training vehicles for mentees and expand her research. These studies, using clinical, genetic and neuropathological data, will be conducted using data from ongoing UCSF/Memory and Aging Center's NIH-funded cohort studies of persons with Alzheimer's disease(AD) . She will examine the role of recently described neurodegenerative changes in modifying the clinical phenotype of AD. In summary, this K24 will enhance Dr. Ginberg's active research program with extensive infrastructure at UCSF to support her goal to remain a leader in neurodegenerative diseases, especially in the field of neuropathology, and to develop a program of excellence for training medical students, trainees, and junior faculty in POR related to age-related neuropathology that is also intended to close the gaps caused by interruption of neuropathology training for neurologists and neurodegenerative disease training for neuropathologists.